Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Idera Pharmaceuticals Inc (NASDAQ:IDRA)

1.41
Delayed Data
As of 4:00pm ET
 0.00 / 0.00%
Today’s Change
1.19
Today|||52-Week Range
3.33
-6.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$208.2M

Company Description

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. Idera Pharmaceuticals was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.

Contact Information

Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge Massachusetts 02139
P:(617) 679-5500
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Vin MilanoPresident, Chief Executive Officer & Director
Louis J. ArcudiCFO, Treasurer & Senior Vice President-Operations
Sudhir A. AgrawalDirector & President-Research
Joanna C. HorobinChief Medical Officer & Senior Vice President
Mark J. CaseySecretary, Senior Vice President & General Counsel